A Message from VGXI Regarding the Coronavirus (COVID-19) Outbreak and VGXI Actions LAST UPDATED July 24, 2020 To our Valued Clients and Business Partners, VGXI recognizes your concerns regarding the potential impact of the coronavirus outbreak on our products and services. VGXI is actively monitoring the situation and will continue to provide… Read More »
Plasmid DNA Manufacturer VGXI, Inc. Completes Land Purchase and Proceeds with Design Development Phase for New Expanded Manufacturing Facility. The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has closed on the purchase of greenfield for a new, expanded manufacturing facility. The… Read More »
Update June 26, 2020: VGXI and GeneOne are pleased with the court’s decision in our favor protecting our company’s intellectual property rights. We have always been willing to manufacture any vaccine candidate for Covid-19, and want to help find a cure. Original Post on June 04, 2020: VGXI was surprised by Inovio’s… Read More »
VGXI, Inc., Geneos Therapeutics’ CDMO partner, completes manufacturing of first GMP Lot under Clinical Manufacturing Supply Agreement. THE WOODLANDS,TX AND PLYMOUTH MEETING, PA – Leading plasmid DNA contract manufacturer VGXI, Inc. announced it has completed accelerated cGMP manufacturing of the first clinical batch of a personalized neoantigen vaccine for its client Geneos… Read More »
News article released this week by the Conroe Economic Development Council announced VGXI’s planned 240,000 square-foot facility to meet increasing demand for high quality plasmid DNA products and services http://www.conroeedc.org/deison-technology-park-provides-increased-capacity-for-vgxi/
Plasmid CDMO VGXI, Inc. Completes Manufacturing and Release of a Vaccine against COVID-19 in Record-Setting Time The Woodlands, TX – VGXI, an industry leading provider of GMP grade plasmid DNA for vaccines and gene therapies, announced it has completed manufacturing and release of a DNA vaccine to combat the COVID-19 pandemic. VGXI… Read More »
Texas-based plasmid DNA manufacturer VGXI, Inc. recognized as a finalist for Best CMO for the ViE Awards of the World Vaccine Congress The Woodlands, TX – VGXI, Inc., a uniquely specialized CDMO providing high quality plasmid DNA-based products and services, announced it has been nominated as a finalist in the category of… Read More »
The 4th Annual Gene Therapy for Rare Disorders will focus on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. Visit VGXI at Booth #6 or meet with one of our representatives during the conference to learn more about how our plasmid manufacturing services can support your gene… Read More »
The World Vaccine Congress is a critical strategic partnering event for the global vaccine industry. Visit our Booth #310 or meet with a representative from VGXI during the conference in April to learn more about how our plasmid manufacturing services can support your vaccine program! Each year at WVC the winners are announced… Read More »
Texas-based plasmid DNA Manufacturer VGXI, Inc. to Enable Accelerated Production of a Vaccine against the 2019 Novel Coronavirus in a CEPI Funded Collaboration The Woodlands, TX – VGXI, a world leading contract manufacturer of clinical grade DNA plasmid, announced it will start production of a DNA vaccine against the novel coronavirus (2019-nCoV)… Read More »
Under a Technology License Agreement with the Houston Methodist Research Institute, Contract Developer and Manufacturer VGXI Achieves Key Milestones with Establishment of Pilot Production Capabilities for RNA-Based Medicines. The Woodlands, TX – VGXI announces successful implementation of new RNA production services through completion of all Phase II initiatives as part of a… Read More »
Plasmid DNA Manufacturer VGXI, Inc. Selects BE&K Building Group as its Design-Build Partner for the Initial Phase of its New and Expanded Manufacturing Facility December 3, 2019, The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services… Read More »
The ISV Annual Congress is the world’s largest scientific conference in the field of vaccines and covers a broad range of topics related to vaccines and immunotherapies. We welcome you to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn more about VGXI’s plasmid manufacturing… Read More »
Sign Up
For more information